SPRINT Stock Overview
Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Sprint Bioscience AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.71 |
| 52 Week High | kr4.69 |
| 52 Week Low | kr0.49 |
| Beta | 1.32 |
| 1 Month Change | 4.28% |
| 3 Month Change | 0.86% |
| 1 Year Change | -84.13% |
| 3 Year Change | -93.70% |
| 5 Year Change | -95.52% |
| Change since IPO | -95.59% |
Recent News & Updates
Shareholder Returns
| SPRINT | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 1.9% | -0.2% | -2.4% |
| 1Y | -84.1% | -2.5% | -12.8% |
Return vs Industry: SPRINT underperformed the Swedish Biotechs industry which returned -4.1% over the past year.
Return vs Market: SPRINT underperformed the Swedish Market which returned -12.2% over the past year.
Price Volatility
| SPRINT volatility | |
|---|---|
| SPRINT Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in SE Market | 12.6% |
| 10% least volatile stocks in SE Market | 3.8% |
Stable Share Price: SPRINT is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: SPRINT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 34 | Mathias Skalmstad | https://www.sprintbioscience.com |
Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes.
Sprint Bioscience AB (publ) Fundamentals Summary
| SPRINT fundamental statistics | |
|---|---|
| Market Cap | kr49.28m |
| Earnings (TTM) | -kr60.41m |
| Revenue (TTM) | kr803.00k |
61.4x
P/S Ratio-0.8x
P/E RatioIs SPRINT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPRINT income statement (TTM) | |
|---|---|
| Revenue | kr803.00k |
| Cost of Revenue | kr12.87m |
| Gross Profit | -kr12.07m |
| Other Expenses | kr48.34m |
| Earnings | -kr60.41m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.87 |
| Gross Margin | -1,503.24% |
| Net Profit Margin | -7,522.67% |
| Debt/Equity Ratio | 0% |
How did SPRINT perform over the long term?
See historical performance and comparison